Ultragenyx Pharmaceutical Lands $45,000,000 Series A Round

  • Feed Type
  • Date
    6/20/2011
  • Company Name
    Ultragenyx Pharmaceutical
  • Mailing Address
    77 Digital Drive Novato, CA 94949
  • Company Description
    Ultragenyx is a new startup focused on developing therapeutics for rare diseases. The company is lead by Emil Kakkis, M.D., Ph.D., former CMO of BioMarin Pharmaceutical, and will build on management’s experience in choosing and developing products with clear mechanisms of action in untreated rare diseases.
  • Website
    http://www.ultragenyx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $45,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    This funding will advance multiple rare disease product programs in the pipeline, as well as the development of new product candidates and partnerships.
  • M&A Terms
  • Venture Investor
    TPG Biotech
  • Venture Investor
    Fidelity BioSciences
  • Venture Investor
    Healthcap Venture Capital
  • Venture Investor
    Pappas Ventures

By posting a comment, you agree to our terms and conditions.